ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / TNON / earnings
SNOA (34) INBS (27) NVNO (33) WOK (51) ⌘ Pro Terminal →

Tenon Medical Inc. (TNON) Next Earnings Date & Expected ±12.5% Move

$2.05 -10.48% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.01

Tenon Medical Inc. (TNON) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $5.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TNON Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TNON stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Tenon Medical Inc. (NASDAQ: TNON) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $2.05 (-10.48% 1D, market cap $5.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, TNON ranks #814 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TNON compare to SNOA and INBS in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), TNON carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 59.8%, and ROIC of -35.0%. By comparison, SNOA (Sonoma Pharmaceuticals Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M) and INBS (Intelligent Bio Solutions Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M). Among the 5-stock peer group, TNON leads on earnings multiple (N/A) while TNON leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TNON?
▼

Per TNON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001560293), Tenon Medical Inc. generated $3.9M in revenue (+20.4% YoY), -$12.6M in net income, and -$11.0M in free cash flow against $10.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.01 (-2.08%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510030
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (6)Whales (3)SEC (8)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-12.7% Base Target
$48 Bull$2 Base$1 Bear
📬 FREE TNON RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TNON)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY TNON SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (27% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 35.8 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
38
Grade E$2.89-13.1% Next Q
Q2 (-2Q)
35
Grade E$2.51-14.7% Next Q
Q3 (-1Q)
33
Grade E$2.14-4.2% Next Q
Current
30
Grade E$2.05-9.6% Hist 90D α
Trajectory: E (38) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a TNON Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While TNON currently carries a cautious 30/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.50) and Max Pain ($2.15) forces dealer call-delta covering toward $47.77.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TNON• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TNON Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 30%NO 70%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.26 Expected Swing
$1.79 (-12.5%)Spot $2.05$2.31 (+12.5%)
MODEL EARNINGS SETUP GAUGE

TNON Quantitative Pre-Earnings Setup: 30/100

Trailing EPS: $4.25 • YoY Revenue Growth: 20.4%

Model Bullish Setup (30/100)Model Risk Weight (70/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$3.9M-$12.6M-$11.0M59.8%
FY 20242024-12-31$3.3M-$13.7M-$10.1M52.2%
FY 20232023-12-31$2.9M-$15.6M-$12.2M59.8%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TNON)

  • ✓Walkthrough of TNON's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
TNON // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -92.25%🛡️ HOLDING TREND SUPPORT
2026-11-03O $2.29H $2.29L $2.05C $2.05VOL 172.5K
RES: $4.71SUP: $1.48SMA50: $3.50SMA200: $16.77
$38.79$28.84$18.88$8.92$-1.04RES $4.71SUP $1.48$2.052026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TNON Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TNON Butterfly Map → + Track TNON →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +20.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on TNON today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TNON. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TNON today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TNON)

Health Care Rank #814 of 1015 ⚔️ SNOA vs TNON Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TNON vs. SNOA, INBS, NVNO, WOK)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Tenon Medical Inc. (TNON) ranks #814 by composite RQD confidence (30/100, grade E) and #932 by equity capitalization ($5.5M). Within this direct 5-issuer industry benchmark cohort, TNON leads on earnings valuation at N/A trailing P/E, while TNON leads on capital efficiency and profitability with -35.0% ROIC and 59.8% gross margin. WOK currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with TNON at 30/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
TNON ACTIVE
Tenon Medical Inc.
E 30/100 — 59.8% -35.0% -10.48% $5.5M Benchmark Subject
SNOA
Sonoma Pharmaceuticals Inc.
E 34/100 — 38.0% -35.0% -8.33% $5.3M /snoa-vs-tnon →
INBS
Intelligent Bio Solutions Inc.
E 27/100 — 40.8% -35.0% -3.82% $5.8M /inbs-vs-tnon →
NVNO
enVVeno Medical Corporation
E 33/100 — — -35.0% -4.13% $4.7M /nvno-vs-tnon →
WOK
WORK Medical Technology Group LTD (Class A)
D 51/100 — — — -9.09% $4.5M /wok-vs-tnon →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001560293 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Tenon Medical Inc. (TNON) reported GAAP revenue of $3.9M (+20.4% vs. FY2024 revenue of $3.3M , and +34.7% cumulative change since FY2023) , GAAP net income of -$12.6M, operating cash flow of -$10.7M, and free cash flow of -$11.0M (-9.5% YoY). On the balance sheet, TNON closed FY2025 with $10.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $3.9M -$12.6M -$10.7M -$11.0M $10.8M —
FY2024 (FY) 2024-12-31 $3.3M -$13.7M -$9.9M -$10.1M $9.8M —
FY2023 (FY) 2023-12-31 $2.9M -$15.6M -$12.2M -$12.2M — —

3. TNON Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TNON stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Tenon Medical Inc. (NASDAQ: TNON) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $2.05 (-10.48% 1D, market cap $5.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, TNON ranks #814 in composite RQD confidence.

How does TNON compare to SNOA and INBS in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), TNON carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 59.8%, and ROIC of -35.0%. By comparison, SNOA (Sonoma Pharmaceuticals Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M) and INBS (Intelligent Bio Solutions Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M). Among the 5-stock peer group, TNON leads on earnings multiple (N/A) while TNON leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TNON?

Per TNON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001560293), Tenon Medical Inc. generated $3.9M in revenue (+20.4% YoY), -$12.6M in net income, and -$11.0M in free cash flow against $10.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TNON trading relative to its 50-day, 200-day, and 52-week technical levels?

TNON last traded at $2.05 (-10.48% on volume of 172,537 shares), positioning the stock -41.43% below its 50-day simple moving average ($3.50) and -87.78% below its 200-day simple moving average ($16.77). Across its 52-week range of $2.05 to $45.50, TNON sits at the 0.0% percentile with a 14-day RSI of 35.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.79 to $2.31).

Direct Sub-Reports: TNON RQD Cockpit TNON 12M Forecast TNON Earnings & Move TNON Dividends & DRIP TNON Insiders & 13F TNON Whale Options TNON Profit Sankey TNON News & Why
ROARABLE RATING BRIEF • RQD 30/100 (E) ✓ SEC XBRL & RQD VERIFIED

TNON — Tenon Medical Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Tenon Medical Inc. (TNON) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.05 (-10.48% 1D, market capitalization $5.5M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 59.8%, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 5/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Tenon Medical Inc. (TNON) is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. It is classified within these sector and industry categories. Per the market data, the company reports a gross margin of 59.8%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Tenon Medical Inc. (TNON) reported $3.9M in annual revenue (up from $3.3M in FY2024, +20.4% YoY) and -$12.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.9M revenue, -$15.6M net income) through FY2025, TNON scaled operating cash flow to -$10.7M and free cash flow to -$11.0M, backed by $10.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 30/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $2.05 – $45.50 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— for upstream or downstream dependencies, sector correlations beyond the Health Care/Medical-Dental Instruments classification, or second-order bottlenecks.

  • Key Question #1: Can TNON sustain or expand its -60.0% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $3.9M and free cash flow of -$11.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is TNON's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

TNON Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Tenon Medical Inc. (TNON) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to TNON Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TNON Bull vs. Bear Conversation Board — What's Your Call at $2.05?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TNON 🐻 33% BEARISH CONVICTION
1. Pick Your Side on TNON:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $2.58 (+25.9%)
📌 Pinned Debate

Revenue grew from $2.9M in FY 2023 to $3.9M in FY 2025 while the Altman Z-Score of 2.5 sits in the reported range.

Long TNON at $2.05 targeting $2.58. Revenue grew from $2.9M in FY 2023 to $3.9M in FY 2025 while the Altman Z-Score of 2.5 sits in the reported range.. Institutional whale score is 3/20 and the risk/reward vs. the $2.05 52-week low is skewed heavily in favor of bulls.

VolSurface_Trader 🐂 BULL

Both sides have a point here — TNON's 8/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $1.68 (-18.0%)
Spot @ $2.05

ROIC of -35% and FCF of -$11.0M against cash of $3.8M point to a cash engine that is not self-funding and reliant on equity raises.

Here is the bear case nobody on the bull side wants to address on TNON: ROIC of -35% and FCF of -$11.0M against cash of $3.8M point to a cash engine that is not self-funding and reliant on equity raises.. At current EV/EBITDA multiples, even a small guidance miss in Medical/Dental Instruments triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%